Analyst consensus rating
Grace Therapeutics Analyst Rating: Strong Buy
GRCE is rated Strong Buy by 2 analysts with a $6.04 target. As of 2026-08-19.
Direct answer
Grace Therapeutics's consensus rating is Strong Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.04.
Forecast evidence checked August 19, 2026.
Get free Grace Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.13
- Average price target
- $6.04
- High price target
- $8.01
- Low price target
- $4.08
- Low target gap
- +91.5%
- Target upside
- +183.8%
- High target gap
- +276.1%
- Target range width
- 184.5%
- Consensus rating
- Strong Buy
- Analysts
- 2
- Evidence date
- August 19, 2026
- Valid through
- August 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Grace Therapeutics?
Grace Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $6.04.
How far are Grace Therapeutics's low and high targets from the recorded price?
The low target implies +91.5%, while the high target implies +276.1%.
How many analysts are included in Grace Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Grace Therapeutics's target upside or downside calculated?
The average target of $6.04 is divided by the recorded price of $2.13, then one is subtracted to produce +183.8%. This does not guarantee a future return.
When was Grace Therapeutics's analyst forecast verified?
The data was verified on 2026-08-19. The dataset is valid through 2026-08-26.